摘要
目的:检测早期乳腺癌患者血清中VEGF及骨髓标本中CK19的表达水平,探讨二者的相互关系及临床意义。方法:应用ELISA法分别检测6例乳腺纤维腺瘤及64例乳腺癌患者血清中VEGF的水平,同时抽取相应的骨髓血标本,应用实时定量逆转录-聚合酶链反应(qRT-PCR)方法检测标本中CK-19的表达水平,并进行相关性分析。结果:VEGF在乳腺癌患者血清中的表达水平明显高于乳腺纤维腺瘤患者,二者差异显著(P=0.012);在HER2阳性患者中,血清VEGF水平明显高于HER2阴性患者(P=0.016)。CK19在乳腺纤维腺瘤患者骨髓标本中未见表达,在乳腺癌患者骨髓血中,阳性表达24例(37.5%),而骨髓中CK19阳性的乳腺癌患者血清VEGF水平显著高于CK19阴性的患者(110.46±90.65 vs 70.88±77.13,P=0.038),且二者的表达呈正相关。结论:早期乳腺癌患者血清VEGF水平与骨髓微转移密切相关,提示VEGF可能参与了肿瘤细胞的侵袭和播散,可作为早期乳腺癌微转移的血清学指标。
Objective:To explore the levels of serum VEGF in early breast cancer and its clinical significance as well as the relationship with bone marrow micrometastases in the patients.Methods: Levels of serum VEGF in 6 cases of breast fibroadenoma and 64 cases of breast cancer were detected by ELISA.Bone marrow CK19 mRNA was detected by qRT-PCR as an index of micrometastases in the patients as well.Correlation between serum VEGF level and bone marrow micrometastasis was analyzed.Results: Levels of serum VEGF in breast cancer were significantly higher compared with those in breast fibroadenoma(P=0.012).A subgroup analysis showed that in HER-2 positive patients,levels of serumVEGF were higher(P=0.016).CK19 mRNA was found in bone marrow of 24 cases of breast cancer and the positive rate was 37.5%.However,it was not detected in the patients with breast fibroadenoma.Mean level of serum VEGF in CK19 positive and negative patients was 110.46±90.65 pg/ml and 70.88±77.13pg/ml,respectively.There was a significant difference between the two groups(P=0.038).Conclusion: Levels of serum VEGF in early breast cancer was closely related with the bone marrow micrometastases.High level of serum VEGF may be a soluble biomarker for the early micrometastasis of breast cancer.
出处
《现代肿瘤医学》
CAS
2012年第2期296-298,共3页
Journal of Modern Oncology
关键词
血管内皮生长因子
乳腺癌
骨髓微转移
vascular endothelial growth factor
breast cancer
bone marrow micrometastases